Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2017-05-22 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于深圳证券交易所2016年年报问询函的回复公告
Annual Report Classification · 95% confidence The document is a detailed reply to an inquiry letter from the Shenzhen Stock Exchange regarding the company's 2016 annual report. It contains extensive financial data, explanations of goodwill allocation and impairment testing, revenue and receivables analysis, financial expenses, management expenses including R&D, and customer sales details. The content is comprehensive and includes substantive financial data and analysis for the full fiscal year 2016. This matches the characteristics of an Annual Report (10-K) or a detailed report related to the annual financial performance. Since it is a reply to an inquiry about the annual report and contains detailed financial disclosures and explanations, it is best classified as an Annual Report (10-K). FY 2016
2017-05-22 Chinese
关于控股股东进行股票质押式回购交易的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement regarding a stock pledge repurchase transaction by a controlling shareholder. It details the number of shares pledged, the pledge start and end dates, the pledgee, and the purpose of the pledge. It also states that the pledge does not affect control or company operations. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about a shareholder's stock pledge transaction, which fits the category of Transaction in Own Shares (POS). The document length is short and focused on this specific transaction, not a full report or earnings release.
2017-05-19 Chinese
2017年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality of procedures and voting results of a company's 2017 first extraordinary general meeting (临时股东大会). It details the convening, attendance, voting procedures, and results of various proposals related to convertible bond issuance and other corporate matters. The document is not a financial report, earnings release, or management discussion, but a legal certification of the shareholder meeting's validity and voting outcomes. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results of a shareholder meeting. The document length is substantial and contains detailed voting results, not just an announcement of a report publication or a brief notice. Therefore, the classification is DVA with high confidence.
2017-05-08 Chinese
2017年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at a shareholders' meeting, specifically the 2017 first extraordinary general meeting of the company. It includes voting results on various proposals related to the issuance of convertible bonds, meeting attendance, and legal opinions on the meeting's validity. The content focuses on the official voting outcomes and procedural details of the shareholders' meeting rather than the meeting materials or presentations themselves. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is substantial and contains detailed voting data, not just a brief announcement or a report publication notice. Therefore, the classification is DVA with high confidence.
2017-05-08 Chinese
关于召开2017年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2017 first extraordinary general meeting (临时股东大会) of 特一药业集团股份有限公司. It includes information about the meeting time, location, agenda items (such as proposals related to convertible bonds issuance), voting procedures including online voting, proxy forms, and attendance confirmations. The document does not contain financial statements or results but is a formal announcement to shareholders about the meeting and the matters to be voted on. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings. The document length is over 7000 characters, indicating it is a full notice rather than a brief announcement. Therefore, the correct classification is PSI.
2017-04-21 Chinese
2017年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled "2017年第一季度报告正文" which translates to "2017 First Quarter Report Main Text." It contains detailed financial data for the first quarter of 2017, including revenue, net profit, cash flow, and other financial indicators. It also includes shareholder information, changes in financial metrics, important matters, and forward-looking statements about the first half of 2017. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length is substantial (over 12,000 characters), and it contains actual financial data and management discussion, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2017
2017-04-21 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.